Clinical evidence of distinct subgroups of astrocytic tumors defined by comparative genomic hybridization

被引:16
作者
Nishizaki, T
Kubota, H
Harada, K
Harada, K
Ito, H
Suzuki, M
Sasaki, K
机构
[1] Yamaguchi Univ, Sch Med, Dept Neurosurg, Ube, Yamaguchi 7558505, Japan
[2] Yamaguchi Univ, Sch Med, Dept Pathol, Ube, Yamaguchi 7558505, Japan
关键词
astrocytic tumors; CGH; cytogenetic aberrations; patient's prognosis; 7p and 8q gains;
D O I
10.1053/hp.2000.6686
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
In astrocytic tumors, the relationship between genetic pathways and patients' prognoses has not been fully investigated. In our studies of astrocytic tumors using comparative genomic hybridization, the presence of 8q gain was mutually exclusive of 7p gain or amplification. In this study, 45 cases of astrocytic tumor were divided into 3 groups: those with 7p gain, cases with 8q gain, or those with neither; and their clinical course, p53, and epidermal growth factor receptor (EGFR) expressions and proliferative activity were then compared. Of the cases examined, 17 (12 glioblastomas and 5 anaplastic astrocytomas) showed 7p gain. Eleven cases (5 glioblastomas, 2 anaplastic, and 4 low-grade astrocytomas) showed 8q gain. p53 accumulation was observed more frequently in cases with 8q gain than in those with 7p gain. Astrocytic tumors with Sq gain occurred more frequently in younger patients than those with 7p gain. Kaplan-Meier survival rate analysis showed higher survival rates in patients with 8q gain than in those with 7p gain. This tendency also was observed when only patients with malignant glioma were included in the survival analysis. Our results provide evidence for distinct clinical manifestations in astrocytic tumors with 8q and 7p gain. Copyright (C) 2000 byW.B. Saunders Company.
引用
收藏
页码:608 / 614
页数:7
相关论文
共 41 条
[1]  
Augenlicht LH, 1997, CANCER RES, V57, P1769
[2]   ISOLATION OF HUMAN-P53-SPECIFIC MONOCLONAL-ANTIBODIES AND THEIR USE IN THE STUDIES OF HUMAN P53 EXPRESSION [J].
BANKS, L ;
MATLASHEWSKI, G ;
CRAWFORD, L .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1986, 159 (03) :529-534
[3]   Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells [J].
Broaddus, WC ;
Chen, ZJ ;
Prabhu, SS ;
Loudon, WG ;
Gillies, GT ;
Phillips, LL ;
Fillmore, H .
NEUROSURGERY, 1997, 41 (04) :908-915
[4]  
CHAVANY C, 1995, MOL PHARMACOL, V48, P738
[5]   RESECTION, BIOPSY, AND SURVIVAL IN MALIGNANT GLIAL NEOPLASMS - A RETROSPECTIVE STUDY OF CLINICAL-PARAMETERS, THERAPY, AND OUTCOME [J].
DEVAUX, BC ;
OFALLON, JR ;
KELLY, PJ .
JOURNAL OF NEUROSURGERY, 1993, 78 (05) :767-775
[6]  
Di X, 1997, J EXP CLIN CANC RES, V16, P389
[7]  
Harada K, 1998, CANCER RES, V58, P4694
[8]  
Hegi ME, 1997, INT J CANCER, V73, P57, DOI 10.1002/(SICI)1097-0215(19970926)73:1<57::AID-IJC10>3.0.CO
[9]  
2-2
[10]   P53 PROTEIN OVEREXPRESSION IDENTIFIES A GROUP OF CENTRAL PRIMITIVE NEUROECTODERMAL TUMORS WITH POOR-PROGNOSIS [J].
JAROS, E ;
LUNEC, J ;
PERRY, RH ;
KELLY, PJ ;
PEARSON, ADJ .
BRITISH JOURNAL OF CANCER, 1993, 68 (04) :801-807